ArticleCancer research communications2022

Targeting Tumor Angiogenesis with the Selective VEGFR-3 Inhibitor EVT801 in Combination with Cancer Immunotherapy.

Michael R Paillasse et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.